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ABSTRACT
The Consensus on restless legs syndrome is an effort of neurologists from several Brazilian states, which tirelessly reviewed the literature
of recent years in search of evidence, both in regard to diagnosis and treatment, according to the Oxford Centre for Evidence-based
Medicine.
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RESUMO
O Consenso em síndrome das pernas inquietas contou com a participação de neurologistas de vários estados brasileiros, os quais
incansavelmente revisaram a literatura dos últimos anos em busca de evidências, tanto no que se refere ao diagnóstico como ao
tratamento, de acordo com a Classificação do Centro de Oxford para Medicina Baseada em Evidências.
Palavras-chave: pernas inquietas, critérios diagnósticos, tratamento.
Protocols or guidelines presented here seek to system-
atize the available knowledge and offer a gold standard
pattern of clinical management, scientifically safer and
consistent for restless legs syndrome. They are evidence-
based recommendations, developed from a review of an
updated scientific literature.
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BRIEF HISTORY
The first known description in Western Medicine that
resembles the framework of Restless Legs Syndrome (RLS)1
– even if not sure of the specific diagnosis2, date of 1685,
in the work of Thomas Willis: "the London Practice of
Physick", in the chapter on sleep disorders (Instructions and
prescripts for the curing Watching Evil, and the Watching
Coma). The description includes several key features of
RLS as feeling restless, occurring at rest, lying in bed, and
with movements of the limbs, both lower and upper, pre-
venting sleep, and recommend treatment with opiates (laud-
anum or tincture opium)3.
In 1945, Dr. Karl-Axel Ekbom, a swedish neurologist, did a
complete characterization of this new clinical entity and
coined the term "restless legs syndrome" with two distinct
forms: one paresthesic and one painful4.
Due to the descriptions of these two authors, recently the
International Restless Legs Syndrome Study Group (IRLSSG)
recommended the use of the eponym Willis-Ekbom Disease
in RLS.
In 1953, Nordlander described the relevance of iron in
RLS treatment5. The relationship between RLS and peri-
odic limb movements (PLMS) was established in Bologna
in 19626. The modern RLS treatment begun in 1982,
when Sevket Akpinar suggested the use of levodopa in
this condition7. Nowadays, RLS is increasingly recognized
as a very frequent condition, affecting around 6%
Brazilian adults8. Even so, RLS still is a very under-
recognized condition9.
In 1995 IRLSSG has been formed as an inter-
national group of researchers on the subject, establishing
diagnostic criteria for RLS. These criteria were subse-
quently modified in 200310. In 2005, the 2nd International
Classification of Sleep Disorders included RLS among
movement disorders related to sleep. In 2011, the criteria
for RLS were again modified as a IRLSSG recommenda-
tion11 (Table 1).
DIAGNOSTIC CRITERIA
RLS is a sensory-motor neurological disease whose main
symptom is an overwhelming need or urge to move the legs
that occurs during periods of rest and inactivity, with a cir-
cadian variation, worse at night, which affects sleep and
affects the quality of individual’s life. This symptom may
affect one or both legs, and in some cases can affect other
parts of the body like the upper limbs. Disease expression
is variable and symptoms can occur daily or once a year,
with mild to very grave intensity10,12,13. Additionally, symp-
toms may show spontaneous remission for varying periods
of time, returning hereafter10.
The diagnosis of RLS is clinical, based solely on reported
symptoms and/or observed in the patient. In 2011, IRLSSG
has modified the diagnostic criteria for RLS, suggesting five
key criteria – which should all be present – and supporting
criteria11.
The need or urge to move the legs, usually
accompanied by discomfort or annoyance
The first essential criterion refers to the primary symp-
tom of RLS: the need or urge to move the legs, which often
is strong and compelling, becoming progressively greater
Table 1. Restless legs syndrome diagnostic criteria.
( 1 ) The need or urge to move the legs, usually accompanied by discomfort or annoyance
( 2 ) Symptoms are worse or exclusively present at rest or inactivity: sitting or lying
( 3 ) Relieving symptoms totally or partially with the movement
( 4 ) The perceived symptoms during rest and inactivity worsen or occur exclusively at night
( 5 ) The above symptoms are not better explained by other diseases or conditions
Support Criteria for the Diagnosis of Restless Legs Syndrome
Positive family history
Clinical course
Positive response to dopaminergic agonist
High PLM index on PSG
Remarks
Eventually the need and/or urge to move the legs may be present without the associated symptoms. Involvement of other areas of the
body like the upper limbs .
For children , the description of these symptoms should be taken by their own words.
When symptoms are very pronounced, relief for the activity can not be perceived , but was previously present.
When symptoms are very intense , worse at night can not be observed but should be previously present.
Conditions that mimic RLS often have been confused with this syndrome, particularly in epidemiological surveys and RLS can also be
present with them.
The criterion of clinical symptoms does not apply to pediatric cases and even some cases of RLS in pregnancy as those caused or
induced by drugs, in which the frequency can be high but limited to the duration of the predisposing condition.
IRLSSG: International Restless Legs Syndrome Study Group; PLM: Lower Limb Movements Periodicals; PSG: Polysomnography. Adapted of 11.
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when relief maneuvers are not performed. This need or urge
to move the legs may or may not be associated with other
unpleasant and uncomfortable symptoms, perceived deep
in the legs between the knees and ankles, which occur with-
out an apparent stimulus10,11,13. Thus, these unpleasant sen-
sations are not mandatory or necessary for the diagnosis,
but if they occur, are manifested in association with the need
to move the legs. These sensations are perceived usually in
the legs, between the knee and ankle, but may involve other
areas of the body such as the arms, abdomen and genitalia.
However, the involvement of other isolated areas of the body
besides the legs are unusual10,11.
The unpleasant sensation is generally difficult to be set
by the patient and can include pain, but does not refer to
cramps (even though the patient may erroneously describe
the symptoms of this form). In cases where there are
only cramps, with pain associated with involuntary
muscle contraction, another diagnosis besides RLS must
be sought10,11. The sensation described by the patient
can include many adjectives and terms here writen in
Portuguese and English8,10,14,15 (Tables 2 and 3).
Symptoms are worse or exclusively present at rest
or inactivity: sitting or lying
The second essential criterion states that the symptoms
of necessity or urgency to move the legs occur or worsen
during periods of rest or inactivity such as, for example, sit-
ting or lying down. For rest and inactivity should be under-
stood not only physical immobility, but also cognitive
inactivity, since increased alertness (as occurs in intense
intellectual activity, such as chat, games video games) can
reduce the intensity of symptoms10. Most patients relate that
symptom intensity increases with longer rest period or inac-
tivity10. There is no specific body position that produces
symptoms, so they can occur in any position as long as
the rest and inactivity are suficient prolonged10.
Situations typically related to symptoms include
moments when the individual is at prolonged rest or have
the leg movements restricted, such as: watching TV, religious
cults, travel (sitting), meetings, theatre, cinema, dining, etc. If
the symptoms resolve or improve with rest, one must con-
template another diagnosis.
Fully or partially alleviate symptoms with the
movement
This criterion stablish that the urgency or need to move
the legs and the associated symptoms improved in whole or
in part with the movement and that this relief remains while
the movement is continued. The more intense the move-
ment, the greater relief of symptoms. For symptomatic
improvement, the individual adopts different strategies, such
as walk, stretch, move, shake, actively swing the legs or
with passive movements as massage10. Besides movement,
Table 2. Complaints of restless legs syndrome.
Inquietação, incômodo Queimação, calor
Irritação Choque
Fisgada, picada Estrangulamento, contração
Dormência Dor, dor no osso, dor “no fundo”
Cansaço Angústia, ansiedade, desespero, aflição, tensão
Coceira, comichão Sensação de pernas nervosas
Formigamento, “formigação” “Ruindade”
Sensação de peso “Cãibras”
Repuxamento Pinicar, “pinicamento”
Vontade de não ficar quieto Friagem nos ossos
Cócega Regionalmente
Vontade de espichar “Farnizim”
“Um bicho dentro da perna” “Gastura”
Words and phrases without english translation.
Table 3. Restless legs syndrome symptomatology.
Restlessness, nuisance
Irritation
Sting
Numbness
Tiredness
Itching
Tingling
Heaviness
Desire to move
Tickle
Willingness to broach
A critter inside leg
Burning, heat
Shock
Strangulation, contraction
Pain, bone pain, pain "in the background"
Distress, anxiety, despair, grief, tension
Feeling nervous legs
Badness
Cramps
Chill in the bones
"Farnizim"
"Gastura"
Modified 8,10,14,15.
262 Arq Neuropsiquiatr 2015;73(3):260-280
symptomatic improvement may also be due to hot or cold
baths and even intense intellectual activities such as reading,
talking, watching TV10.
In cases where the symptoms are very severe, the relief
by movement may not be noticed, but it was previously
present10,11. Movements typically referred by the patients
include: walking, stretching, crash grounded, massaging,
hot bath, regionally, rubbing or shaking legs. It is observed
that the relief persists while the movement is performed
and this should be continued (not just only one motion
for relief or improvement of symptoms).
The perceived symptoms during rest and inactivity
worsen or occur exclusively at night
The fourth essential criterion refers to the circadian char-
acteristic of RLS, with worsening of symptoms in the after-
noon and evening. When the patient’s symptoms are more
severe, symptoms may occur at other times of the day.
However, the patient will be able to remember that these
were earlier more intense in the afternoon or at night10,11.
The above symptoms are not better explained by
other diseases or conditions:
N Myalgia
N Venous Stasis
N Edema of the lower limbs
N Arthritis
N Cramps
N Positional Discomfort
N Rhythmic movements such as tics and lower limbs
mannerisms
N Leg swinging
CLINICAL EVOLUTION
(A) Chronic persistent RLS: symptoms, if left untreated,
may occur on average at least twice a week in the past year;
(B) Intermittent RLS: symptoms, if left untreated, occur
on average less than twice a week, in the last year, with at
least 5 episodes throughout life.
CLINICAL RELEVANCE
RLS symptoms cause distress or impairment in social,
occupational, educational or other important areas of func-
tioning by the impact on sleep, on the sense of energy and
vitality, on daily activities, behavior, cognition or mood.
SUPPORTING CRITERIA FOR RLS DIAGNOSIS
In addition to the RLS essential diagnostic criteria sup-
porting criteria allow greater diagnostic certainty11.
Positive family history
It can often be identified among carriers of the condition,
it is estimated that first-degree relatives are at 3-5 times risk to
develop RLS10,12. The earlier onset of RLS symptoms – before
the 34 to 45 years old – indicates an increased family risk12.
Clinical course
Two distinct RLS phenotypes are recognized: (1) primary
or familiar with a genetic predisposition and an earlier onset
of symptoms; (2) secondary, associated with iron deficiency
conditions (iron deficiency anemia, pregnancy, frequent
blood donation, renal failure), with other clinical and neuro-
logical disorders and substances (Table 4). RLS is considered
a chronic disorder, especially the idiopathic form, with pro-
gression of symptoms in the course of its evolution. The
evolution of secondary RLS is related to the underlying dis-
ease, with the possibility of remission of symptoms as
occurs, for example, after pregnancy or renal transplant.
Positive response to dopamine agonist
Practically all patients with RLS have an initial response
to the treatment with dopaminergic agents (levodopa or
dopamine agonists – see treatment section) at doses lower
than those used for the treatment of Parkinson’s disease.
In fact, approximately 90% of patients treated with dopami-
nergic agents referred some symptomatic relief. Therefore,
the symptomatic response to relatively low doses of these
Table 4. Conditions associated with restless legs syndrome.
Insomnia Vascular insifficiency
Renal failure Iron deficiency anemia
Hepatic failure Use of alcohol
COPD Use of caffeine
Fibromyalgia Medicines
Multiple Sclerosis Metoclopramide
Parkinson’s disease Antihistamines
Charcot-Marie type II Lithium carbonate
Gastrectomy or bariatric surgery Neuroleptic dopamine antagonists
Gestation Antidepressants (except bupropion)
Rheumatoid arthritis Levothyroxine
Modified 10,29
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drugs is highly suggestive of RLS diagnosis10,13. The levodopa
test, consisting on the administration of levodopa- benserazide
at a dose of 100/25 mg showed a high sensitivity (80%-88%)
and specificity (100%) for the diagnosis of RLS16. Furthermore,
administration of dopamine antagonists such as anti-
psychotics and antiemetics, result in increased intensity of
symtoms13.
High PLM index on PSG
The periodic movements of the lower limbs, both awake
as in sleep, are considered as the motor expression of RLS.12
It is estimated that around 80% of patients with RLS exhibit
periodic limb movements in sleep. This number is lower in
children. PLMS are non-specific for the diagnosis of RLS
because they often occur in association with other disorders
such as narcolepsy, REM sleep behavior disorder, obstructive
sleep apnea (OSA) and even in normal individuals (especially
the elderly)10,13.
EPIDEMIOLOGY
The prevalence of RLS is between 5%-10%17,18,19,20. In a
study conducted in a Brazilian city, RLS prevalence was esti-
mated at 6.4%8. There was an increasing prevalence by age
and a greater involvement of women, at a rate of two women
to one man. Possible explanations for the higher prevalence
in women include: (1) that women perceive and report
symptoms differently from men, (2) the presence of hor-
monal differences among genders, (3) the reduction of iron
stores in women.
Furthermore, pregnancy may be an important risk factor
to develop RLS in those women who have a family history of
RLS. The effect of pregnancy justified most of the difference
in the prevalence of RLS among genders21.
It has been recurrently observed a decrease in the preval-
ence of RLS in individuals older than 60/70 years of age17,18,22.
Men with RLS, compared to individuals without RLS, have
higher mortality independent to other known risk factors
such as cancer, cardiovascular disease and hypertension23.
DIFFERENTIAL DIAGNOSIS24,25,26,27,28
N Neuroleptic-induced akathisia
N Hypotensive akathisia
N Peripheral neuropathy
N Lumbar radiculopathy and myelopathy
N Vascular and neurogenic claudication
N Chronic pain syndrome (lumbar, cervical)
N Fibromyalgia
N Arthritis of the lower limbs
N Positional Discomfort
N Nocturnal cramps
N Sleep Myoclonus
N Depression
N Voluntary movements, such as swinging the legs or
tapping the feet, are observed in anxiogenic and tedious
situations
N Peripheral vascular insufficiency and varicose veins
N Painful legs and moving toes
N Curse of Vesper
N Growing pains in children
Allen and Earley24 highlight six key points in the differ-
ential diagnosis of RLS in relation to other diseases:
(i) RLS is triggered by rest and not related to another
activity previously performed by the individual. This
feeling, though not related to a specific position,
occurs when remaining seated or lying down and not
only when sitting.
(ii) It is a focal akathisia, defined as the inner need to
move a specific body part, in this case the leg. When
symptoms are severe, other parts of the body may be
affected, but the legs are always affected.
(iii) The symptoms are immediately stopped or relieved
with movement. This differs from the other pathol-
ogies such as chronic pain syndromes or vascular
compression.
(iv) The relief or symptomatic improvement persists as
long as the movement is continued, returning as
soon as the individual interrupt it.
(v) There is usually a time of day when RLS symptoms
are not present or are less intense. In this period of
the day, the individual may remain more time sitting
or lying down, before symptoms occur. The circadian
pattern of RLS is such that the patient usually does
not experience discomfort in the morning, with
exacerbation of symptoms in the afternoon and
evening.
(vi) The physical examination is usually normal in RLS.
No physical changes in the lower limbs, such as
muscle atrophy, skin changes and phaneros changes,
varices, etc.
In a recent review of drug induced RLS, all studies that
evaluated induction or exacerbation of RLS were considered
as level IV evidence29. The vast majority of studies did not
control additional risk factors, eg, concomitant use of alco-
hol, tobacco or caffeine. Likewise, there was no control for
concomitant use of other drugs, a common practice in
patients under psychiatric treatment. In that review, the stron-
gest evidence regarding RLS induced or exacerbated by drugs
was related to use of escitalopram, fluoxetine, levodopa-carbi-
dopa and pergolide (augmentation), levothyroxine, mianserin,
mirtazapine, olanzapine and tramadol (augmentation).
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COMPLEMENTARY TESTS
The selection of laboratory tests should be performed
according to the clinical suspicion (as primary or secondary).
Primary form:
N CBC, ferritin, transferrin total saturation (CONSENSUS).
Secondary forms:
N CBC, ferritin, transferrin total saturation;
N Additional laboratory tests according to clinical suspicion
of underlying pathology (eg, urea, glucose, TSH, liver
enzymes) (CONSENSUS).
Ferritin values below 50 mg/l are associated with
increased risk of RLS, even in patients with normal hemo-
globin, with greater severity of symptoms and decreased
sleep efficiency. Thus, the assessment of serum ferritin is
recommended in all patients with RLS30,31.
ROLE OF THE PSG TEST IN THE EVALUATION OF RLS
The diagnosis of RLS is essentially clinical, based on the
diagnostic criteria previously mentioned. Therefore, the PSG
is not necessary for diagnosis. However, in situations where
the clinical diagnosis is doubtful, the PSG provides addi-
tional resources, since about 80% of RLS patients have
PLMS32. The PLMs are described as rhythmic hallux exten-
sions with the heel dorsiflexion and occasional bending of
the knee and hip joint, occurring during sleep or wakeful-
ness, with a tendency to concentrate during NREM sleep,
in series at regular intervals.
Patients with low intensity symptoms, persistence of symp-
toms despite treatment and possible sleep disordered breathing
are examples of situations in which the PSG can be useful in the
management of RLS33. Polysomnography findings in RLS may
include, in addition to increasing rate of periodic movements
of the lower limbs, increased sleep latency, sleep fragmentation,
reduced total sleep time and reduction of slow wave sleep10,12.
OTHER METHODS OF ASSESSMENT
The actigraphy with accelerometer, portable device capable
of detecting bodymovements, has no well established role in the
routine clinical evaluation of patients with RLS. Therefore we do
not recommend the use of actigraphy in the diagnosis, assess-
ment of disease severity, or therapeutic indication. However,
actigraphy may be considered for evaluating the therapeutic
effects according to the recommendations of AASM34.
The suggested immobilization test (SIT) records surface
electromyography with electrodes placement on the tibialis
anterior muscles during immobilization at night. This test
aims, through the reproduction of the conditions related
to the onset of symptoms, change the clinical manifestations
into objective measures. This is achieved through a ques-
tionnaire and measurement of periodic limb movements
occurring during wakefulness (PLMW). With this test we
can see that PLMW are significantly more frequent in
patients with RLS than in patients with PLMD connected
to other causes. The test may represent a diagnostic aid
and provide an objective measure to therapeutic control35.
CARDIOVASCULAR CONSEQUENCES
Studies suggesting cardiovascular changes in RLS are
recent. The reduction in total sleep time caused by the syn-
drome and the association with the PLMs may suggest that
an increase in sympathetic activity and even increased insu-
lin resistance may occur in the long term. However, RLS is
also more frequent in patients with renal, hepatic, neuro-
logical and reumatic diseases36,37, and may even increase
cardiovascular risk in these patients38,39.
Population-based cross-sectional studies have suggested
an association between cardiovascular disease and RLS.
Ulfberg and cols40 showed that men who had RLS reported
greater presence of heart disease (OR = 2.5, 95%CI 1.4-4.3)
and hypertension (OR = 1.5, 95%CI 0.9-2.4). Ohayon &
Roth41 found 1.36 (95%CI 1.14-1.61, p , 0.001) risk for hyper-
tension of and 1.41 for coronary heart disease (95%CI 1.06-1.88,
p , 0.05), after adjusting for confounding variables.
Cohort studies, Wisconsin Sleep Cohort and Sleep Heart
Health Study, both found more reports of cardiovascular dis-
ease among people with RLS, especially with daily symptoms
(OR = 2.58, 95%CI 1.38-4.84). In the Sleep Heart Health Study
they found 2 times higher chance of having coronary heart
disease or cardiovascular disease even after adjustment for
age, gender, ethnicity, BMI, diabetes mellitus, systolic blood
pressure, use of antihypertensive medication, cholesterol and
smoking history. The risk was higher in patients with more fre-
quent symptoms, occuring more than 16 times per month42,43.
In a more recent study with 65,544 women (41-58 years
old), the adjusted odds for hypertension in women with
RLS symptoms over 15 times per month was 1.41
(95%CI 1.24-1.61) compared to those without symptoms
(p , 0.0001)44. In the Women’s Health Study, no association
was found between the presence of RLS and cardiovascular
events45. Only after regression analysis models, the study
showed a weak association of RLS with BMI $ 35 kg/m2
(OR = 1.35, 95%CI 1:17 to 1:56), diabetes (OR = 1.19 , 95%CI
1:04 to 1:35), dyslipidemia (OR = 1.17 , 95%CI 1:09 to 1:26),
smoking (OR $ 15 cigarettes/day = 1.41, 95%CI 1.19-1.66)
and the physical activity (OR for $ exercises 4x/week = 0.84;
95%CI 0.74-0.95).
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Regarding prospective studies, one evaluated 70,977
women (average age 67 y.o) initially without coronary heart
disease or stroke, from 2002-2008. Women with RLS lasting
three years or more had a higher chance of coronary heart
disease (defined as fatal or non- fatal myocardial infarction),
with hazard ratios of 1.72 (95%CI 1.09-2.73, p = 0.03)46. Two
other studies have evaluated health professionals (29,756
women aged 45 or more and 19,182 men aged 40 years or
more). The authors found no increased risk for cardiovascu-
lar events with and without the exclusion of participants
with comorbidities47.
Finally, with regard to mortality, there were reports of
increased risk (hazard ratio = 1.85, 95%CI 1.20-2.85, p = 0.005)
in women with RLS and daytime sleepiness after follow-up
of 20 years48. Other prospective studies, also cohort, with follow-
up from 6 to 11 years, found no increase in mortality for all
causes49.
From the standpoint of clinical disease to the risk of RLS,
Winter et al.50 found that the presence of diabetes signific-
antly increased chance of RLS in men (OR = 1.41, 95%CI
1.21 to 1.65) n = 22,786 with an average age of 67.8 years old.
In summary, the literature suggests increased cardio-
vascular risk in patients with RLS associated with the sever-
ity and frequency of symptoms. But a causal relationship can
not yet be established, since there are few prospective stud-
ies and with appropriate design.
RECOMMENDATION
Patients with restless legs syndrome should be screened
and treated for cardiovascular risk factors (level B of evid-
ence).
CONSIDERATIONS ON THE USE OF LEVODOPA IN
THE TREATMENT OF RESTLESS LEGS SYNDROME
Levodopa is effective, in the short term, to treat Restless
Legs Syndrome (RLS), improving symptoms, quality of sleep
and quality of life (Class 1, level B)52. However, dopamine
agonists are superior to levodopa in improving symptoms
related to quality of life and sleep duration52.
The use of levodopa can be more advantageous than
other therapies for patients with intermittent symptoms of
RLS not requiring daily treatment (using "as needed")51.
The tolerability of levodopa is greater than that of cabergo-
line, but evidence to the long term treatment is limited3. In
addition, levodopa is at greater risk of augmentation than
the dopamine agonists, pramipexole and cabergolina51.
It should be noted that the recommendation of levodopa/
benserazide changed compared to the previous criteria,
ceasing to be "standard" (default) and rising to level of
recommendation "guideline" – is not standard but is eligible,
high level of evidence, approved "off-label" by the FDA (not
prohibited but not recommended), balanced risk benefit
especially for occasional use (this means that the benefits
do not outweigh the risks much difference).
TREATMENT WITH DOPAMINE AGONISTS (DA)
Dopamine agonists are the most studied agents used to
treat RLS. The largest quantity and quality of clinical studies
has led to an increasing body of scientific evidence regarding
the use of these drugs. These dopaminergic agents may be
divided into two groups: non-ergot and ergot derivatives.
The non-ergots available in Brazil are pramipexole and piri-
bedil. The ergots are pergolide, lisuride and bromocriptine.
After a survey in Cochrane databases, MEDLINE,
EMBASE, PsycINFO, and www.clinicaltrials.gov and
www.clinicalstudyresults.org, it were found 15 randomized
controlled trials investigating the use of dopamine agonists
versus placebo in the treatment of moderate to severe RLS
(considering the available drugs in Brazil). In most studies,
the diagnostic criteria for RLS followed ICSD-2
(International Classification of Sleep Disorders) or the IRLS
(International RLS Study Group) (Table 1).
MAJOR NON-ERGOT DA
Pramipexole
Pramipexole is an agonist of D1, D2 and D3 dopaminergic
receptors, with greater affinity for D3. It is the most studied
(see major studies in Table 4). We found 8 studies (Table 5)
with evidence level 1A for their short-term efficacy (up to 12
weeks) and 3 other long-term studies (up to one year) reveal-
ing persistent effect in more than 80% of patients53,54,55. All
the studies have shown improvement in symptoms as
assessed by tools and questionnaires. The available presenta-
tions are tablets of 0.125 / 0.25 / 0.5 / 0.75 / 1.0 and 1.5 mg or
extended-release tablets of 0.375 / 0.75 / 1.5 / 3.0 and 4.5 mg.
The half-life is 8 to 12 hours and the onset of action of 1-2 h
after ingestion. The recommended initial dose is 0.125 mg,
two hours before the onset of symptoms, but we may gradu-
ally titrate the dose and/or schedule according to the thera-
peutic response.
Implications for clinical practice: grade A recommenda-
tion for the treatment of moderate to severe RLS, based
on evidence level 1A .
Piribedil
Piribedil is an agonist of dopamine D2/D3 receptor and
alpha-2 adrenergic antagonist. This drug is used sporadically
to treat disorders of vascular vestibular-cochlear origin and
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other vasculopathies. The drug reaches its maximum plasma
concentration one hour after oral administration and is
biphasic, with plasma elimination half-life of 1.7 to 6, 9 hours.
In a pilot study involving 13 patients it was observed a subject-
ive improvement of nighttime symptoms of RLS in 11 partici-
pantes56. There are no randomized placebo-controlled trials.
Implications for clinical practice: recommendation grade
B based on the existence of one study with level of evidence
2C. Therefore piribedil is considered possibly effective in the
treatment of moderarte to severe RLS and is recommended
as a treatment option but not as an initial treatment.
Ropinirole
Ropinirole is a dopamine agonist that acts mainly in the
D2 and D3 receptors with higher affinity to D3.
Presentations are tablets of 0.25, 0.5, 1.0, 2.0 and 5.0 mg.
Ropinirole reaches its maximum plasma concentration
between 1 and 2 hours after oral administration and has a
half life of 6 hours. It is not yet available in Brazil. Along with
pramipexole, ropinirole is recommended for the treatment of
RLS by American and European consensus with the same
degree of recommendation (A) and level of evidence (1A).
This recommendation is endorsed by at least seven rando-
mized, placebo controlled double blind trials51,57.
Implications for clinical practice: grade A recommenda-
tion for the treatment of moderate to severe RLS, based
on evidence level 1A.
Rotigotine
Rotigotine is also not yet available in Brazil. It is D1, D2,
D3, D4 and D5 agonist plus 5HT1A agonist and alpha2
adrenergic. The transdermal 1 mg presentation is to be
applied once a day whereas the most studied for SPI were
2 to 4 mg. The drug has been studied in five randomized,
double blind, placebo controlled trials, lasting between one
week and six months. The efficacy of rotigotine was superior
to placebo in all parameters evaluated (IRLS, CGI, MPM and
QoL).
Implications for clinical practice: grade A recommenda-
tion for the treatment of moderate to severe RLS, based
on evidence level 1A.
Adverse effects related to non-ergot DA
These drugs are generally well tolerated in the treat-
ment of RLS, possibly by the use of lower doses and lower
prevalence of comorbidities when comparing SPI to
Parkinson’s disease, for example. The rare adverse effects
are from weak to moderate intensity and typical for non-
ergot AD: dopamine dysregulation syndrome (disorders of
addiction and impulse control), nausea, headache, som-
nolence, orthostatic hypotension, mental confusion, agita-
tion, hallucinations and nasopharyngitis. These effects
were reported by 23% of patients and are usually solved
with drug withdrawal or reduction of dose58,59,60,61. With
regard to augmentation, there is a special session for that
matter later on this article. However it should be noted
that the evidences point to an incidence of up to 30% with
the use of pramipexole in three years, up to 3% in 6 months
of ropinirole and 13.2% up to 5 years with rotigotina57.
Assessment of augmentation depends on long-term
inquiry.
Table 5. Randomized, double-blind, placebo-controlled studies with dopamine agonists (available in Brazil) in RLS treatment.
Agent Study N Duration Dose* (mg) Parameter#
Pramipexole Ferini-Strambi et al., 200818 357 12 weeks 0.75 IRLS, QoL, MOS
Inoue et al., 201019 41 6 weeks 0.75 IRLS, MPM, PGI, CGI, PSQI
Montagna et al., 201120 402 12 weeks 0.75 IRLS
Montplaisir et al., 199921 10 4 weeks 1.5 MPM, AS
Oertel et al., 200722 338 6 weeks 0.75 IRLS, CGI, PGI
Partinen et al., 200623 86 3 weeks 0.75 IRLS, CGI
Winkelman et al., 200624 339 12 weeks 0.75 IRLS, CGI, QoL
BI 248.616, 200825 376 6 weeks 0.25 IRLS, CGI, PGI
Pergolide Earley et al., 199826 16 18 days 0.65 MPM, ES, SA
Pieta et al., 199827 8 10 days 2.5 PLM, SE, SA
Trenkwalder et al., 200411 83 48 weeks 0.75 IRLS, PLM, SE, PGI
Wetter et al. 199928 28 4 weeks 0.75 MPM, TTS, AS
Bromocriptine Walters et al., 198829 6 4 weeks 7.5 SA, PLM, TST
Lisuride Benes et al., 200514 153 12 weeks 10 mg/48h IRLS, CGI, MPM
Benes et al., 200817 231 12 weeks 7.5mg/48h** IRLS, CGI, PLM
Cabergoline Stiasny-Kolster et al., 200430 80 5 weeks 0.5–2 IRLS
Oertel et al., 200631 43 5 weeks 2.0 IRLS, PLM, QoL
Trenkwalder et al., 200732 204 30 weeks 2–3## IRLS, CGI, QoL
*In most of the studies there was a gradual dose increase beginning with the minimal doses; **Comparative study with Ropinirole 3.0 mg. #Parâmetros que
refletiram redução dos sintomas de SPI quando comparados ao placebo ou outra droga; ##Comparative study with levodopa/bezerasida 200/50. IRLS:
International Scale Severity of the International Restless Legs Syndrome study group; SA: Subjective avaliation; PGI: Patient Global Impression; CGI: Clinical
Global Impression; QoL: escala visual de qualidade de vida; TSL: Total sleep time; PLM: Periodic limb movement; SE: Sleep efficiency; MOS: medical
outcome scale; PSQI: Pittsburgh Sleep Questionary Index.
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MAJOR DA ERGOT
Pergolide
Pergolide is an ergolinic dopaminergic agonist with
higher affinity for D1 and D2 receptors. It still exerts a sero-
toninergic effect on 5HT1A, 5HT1B, 5HT2A, and 5HT2B 5HT2C
receptors. It is available in tablets of 0.05 / 0.25 and 1.0 mg.
Currently, four randomized placebo-controlled, double
blind trials show superior efficacy of pergolide to placebo
in containing the symptoms of RLS (Table 1). A long-term
study revealed no serious adverse effects of pergolide, over
48 weeks, at doses from 0.5 to 0.75 mg62. However, although
effective in the treatment of RLS, pergolide was withdrawn
from the U.S. market due to the risk of cardiac valvulopathy
(derived from the experience over use of ergot in the treat-
ment of Parkinson’s disease and prolactinomas and
endorsed by study recente63.
Implications for clinical practice: due to the side effect
profile, pergolide is considered effective but not recom-
mended as initial treatment of RLS (grade A recommenda-
tion supported by evidence level 1A).
Bromocriptine
Ergolinic dopamine agonist with action at D1 and D2
(greater affinity for D2) and serotonin (5-HT2B) and adrener-
gic weak effects. The peak plasma concentration occurs
approximately 70 minutes after oral administraçãoo and
its elimination half-life is 6-8 hours. The available presenta-
tions are in tablets of 2.5 and 5.0 mg. Like other ergot DA,
its use in Parkinson’s disease and prolactinoma was asso-
ciated with increased incidence of serious complications
such as valvular fibrosis cardíaca64.
Implications for clinical practice: due to the side effect
profile and lack of data endorsing its effectiveness, bromo-
criptine is considered probably effective in the short term,
but is not recommended as a treatment of RLS (grade A
recommendation with level of evidence 1B).
Lisuride
Lisuride is an ergolinic dopamine D2, D3 and D4 agonist
receptor, beyond agonist serotonin 5HT1A and 5HT2A sero-
tonin agonist and 5HT2B antagonist. It reaches maximum
plasma concentration from 1.1 to 1.3 hours after oral admin-
istration and has a half-life of one to three hours. A rando-
mized study of 153 patients using transdermal lisuride to
severe RLS showed significant improvement on PLM index,
CGI-I and IRLS65. Reviewing the literature, Hofmann and col-
leagues justify the lower tendency to fibrotic disease asso-
ciated with the use of lisuride to 5HT2B serotonine
antagonism66. It was was estimated that in 360,000 patients
studied none has shown cardiac fibrosis with rare cases of
other types of fibrosis. This medication is available in 0,2 mg
tablets66.
Implications for clinical practice: due to the side effect
profile lisuride is considered effective but not recommended
as a treatment of RLS (grade A recommendation, level of
evidence 1A – studies with transdermal presentation, not
available in Brazil).
Cabergoline
Ergolinic DA preferential for D2 and 5HT2B agonist. Its
main distinguishing feature is a long half life, around 65
hours. Onset of action occurs about three hours after oral
intake. The presentation is in 0.5 mg tablet. To date three
randomized placebo controlled, double blind trials show effi-
cacy of cabergoline over placebo and levodopa in controlling
the symptoms of RLS although levodopa was better toler-
ated than cabergolida (Table 5).
Implications for clinical practice: due to the side effect
profile, cabergoline is considered effective but not recom-
mended as initial treatment for RLS, unless failure on ther-
apy with drugs with better safety profile occurs (Grade A
recommendation supported by evidence level 1A).
Adverse effects related to ergot DA
The same as the other DA, but with lower incidence67.
However, it should be noted the risk for cardiac valvular,
lung, pleural, pericardial and retroperitoneal fibrosis.
Despite proven efficacy in controlling symptoms of RLS
and the low incidence of augmentation, ergot DA are not
recommended as first choice treatment of RLS due to the
risk of serious side effects, mainly fibrotic disease and shoul
be avoided.
In summary, with regard to the treatment of RLS with
dopaminergic agonists, although it is a traditional practice,
there is still a paucity of studies describing the safety and
long-term efficacy of these drugs in patients with RLS (med-
ian duration of clinical trials known is 10 weeks, ranging
from 1 to 30 weeks). Furthermore, in general, the therapeutic
effects between the various treatment options for RLS have
not been compared, except the few studies comparing the
effectiveness between different dopamine agonists which
showed greater efficacy of ergolínics67. Another demand is
a specific approach to augmentation related to these drugs.
Based on the information presented above, the recom-
mendations of the Brazilian experts on the treatment of
RLS with dopaminergic agonists are summarized in Table 6.
ALPHA DELTA LIGANDS AGENTS
Gabapentin
Gabapentin is an agonist a2d-1 subunit complex calcium
channel voltage-dependent present on neurons, for orally
exclusive use. Gabapentin is traditionally used to treat
epilepsy and neuropathic pain. The presentations in the
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domestic market are with 300, 400 and 600 mg tablets and
400 mg and 300 capsules. The maximum recommended
dose for adults is 3600 mg per day, divided into 3-4 doses,
and the use should be recommended for patients older than
12 years of age. The most prevalent side effects are drow-
siness, dizziness, fatigue, headache, and tremor.
However, gabapentin has been used in the treatment of
RLS with therapeutic action confirmed in a few studies,
and is considered the first non-dopaminergic agent that
failed to demonstrate efficacy in the treatment of RLS.
There are only two controlled studies on gabapentin as used
in Brazil. The first study demonstrated its superiority over
placebo68, and the second study with only 8 patients demon-
strated efficacy when gabapentin was compared with ropi-
nirole69.
The review of articles with quality criteria to assess the
action of gabapentin in the treatment of RLS in patients with
chronic renal failure showed only two articles. Thorp and
colleagues demonstrated the benefit of the use of gabapentin
in a crossing over type study with 16 chronic renal patients
using doses ranging from 200 to 300 mg to day70.
Micozkadioglu and collaborators showed improvement of
RLS symptoms in 15 patients on hemodialysis after gaba-
pentin at doses of 125 to 200 mg/day71.
The positive results in the symptoms of RLS give
Gabapentin Class I recommendation for use, but with level
of evidence B due to the limited number of studies in general
populations and chronic renal failure.
Pregabalin
Pregabalin is an agonist a2d-1 subunit complex calcium
channel voltage-dependent present in neurons, for exclusive
use by oral administration. Pregabalin is traditionally used
for the treatment of epilepsy, neuropathic pain, fibromyalgia
and generalized anxiety disorder. The presentations in the
domestic market are tablets of 75 and 150 mg. The max-
imum recommended dose for adults is 600 mg daily, usually
divided into two doses, with the recommended use in
patients older than 12 years of age. The most prevalent side
effects are drowsiness and dizziness.
Pregabalin has also been studied in recent years to treat
RLS with more robust results than gabapentin. Two studies
demonstrated that pregabalin can be used safely.
The first study was carried out with 6 weeks duration in a
group of RLS patients classified as moderate to severe. These
patients were divided into 6 groups to analyze the effective-
ness of the medication and the most appropriate dose in mg
(50/100/150/300/450) and 114 patients using pregabalin ver-
sus 23 patients on placebo. As a result, the authors demon-
strated symptoms reduction from 123.9 mg dose, i.e. only
doses greater than or equal to 150 mg were eficacious72.
Side effects were also dose dependent, the most common
being dizziness and drowsiness followed by dry mouth,
fatigue, headache, abnormal dreams72.
The second study, a case control lasting 12 weeks,
showed improvement with a dose of 300 mg, where 30
patients with idiopathic RLS were compared with 28 con-
trols. There was an improvement of RLS symptoms,
improvement in sleep architecture and reduction of periodic
limb movements73. In this study, gait instability was the most
frequently observed side effect followed by drowsiness.
Other side effects observed were headache, blurred vision,
dizziness, dry mouth, dyslalia allergic rash and nausea.
There are no studies comparing pregabalin with other drugs
for RLS.
The search for articles with quality criteria for assessing
the effect of pregabalin in the treatment of RLS in patients
with peripheral neuropathy showed only one article.
Sommer and colleagues demonstrated the benefit of using
prebagalin in 16 patients with neuropathic pain at doses
between 150 and 600 mg a day74.
Pregabalin treatment also resulted in improvement in
symptoms of RLS patients, receiving Class I recommenda-
tion for its use, but level of evidence B for general popula-
tions and patients with neuropathic pain (Table 7).
TREATMENT OF RLS BY OPIOID AGENTS
For several decades, opioids have been used empirically
as an alternative for the treatment of RLS. There are no
Class I studies on the treatment of Restless Legs
Syndrome by opioids. A Class II study indicates that oxyco-
done is probably effective in the pharmacological treatment
of RLS75. A Class II study evaluated the drug propoxyphene.
However, the outcomes were periodic leg movements and
measures of sleep quality, without a direct assessment of
RLS symptoms76. For other opioids (codeine, methadone, tra-
madol and others) there are only studies of Classes III and
IV77,78,79,80. Some of these studies report mainly on the toler-
ability of opioids in the long term, providing only indirect
data80 or no information on clinical effectiveness101. The data
that draws attention in studies of Ondo and Silver79,80 is that
all patients who abandoned treatment with opioids (around
15% in total), did it in the first year of treatment, with no
dropouts from the second year. In a retrospective study of
Table 6. Dopaminergic agonists for restless legs syndrome
treatment (available in Brazil).
Drug Recommended
Pramipexole Recommended
Piribedil Optional
Bromocriptine Contraindicated
Cabergoline Optional
Pergolide Contraindicated
Lisuride Optional
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29 patients using methadone after failed treatment with
dopaminergic agents, 63% of patients were still on methad-
one after 23 ± 12 months of treatment, all reporting a reduc-
tion of at least 75% of symptoms without augmentation.
All these studies, coupled with clinical experience suggests
that opioids are particularly useful for patients with refractory
forms of RLS and/or development of augmentation when
treated with other agents, or for use as needed in patients
with intermitent symptoms51,81. Pharmacological efficacy of
opioids seems to be specifically related to Mu type, as opposed
to Kappa type opioid receptor agonism, which has practical
implications for drug choice79. Moreover, effectiveness of
opioid therapy seems to depend, in some way, on interaction
with dopaminergic transmission79.
The average recommended oxycodone dose is 10mg (ran-
ging from 5 to 20 mg) administered as a single dose 2 hours
before the usual onset of symptoms75. For tramadol the
recommended dose is 50-400mg77,81 and for methadone
5-40 mg79,80.
The most common side effects are: constipation, seda-
tion, a possible risk for the development or worsening of
sleep breathing disorders78 and a non-defined potential for
abuse in predisposed patient. Therefore, patients should be
clinically monitored for these symptoms. In general, how-
ever, these drugs are well tolerated51. There is a case report
of augmentation with long term use of tramadol82. Another
study reported lower risk of augmentation with methadone
than with long term use of dopaminergic agents82 (Tables 8
and 9).
IRON IN THE TREATMENT OF RLS
Although there are data suggesting that iron is associated
with the pathophysiology of RLS and various data in the lit-
erature reporting the benefits of replacing oral or parenteral
iron in patients with RLS, there are no good-quality studies
that give scientific support decisions about their effective-
ness and safety. In summary, the studies do not allow us
to say whether the oral or parenteral iron is beneficial to
patients with RLS.
A Cochrane systematic review83 is the best synthesis of
knowledge about available iron and SPI. The authors con-
cluded that there is no clear evidence of the role of iron in
the treatment of RLS. The primary studies did not support
or not to recommend the use of iron in the treatment of this
disease. An important aspect is that the adverse effect was
not different between the study groups and placebo.
The systematic review allowed the identification of two
studies using the primary route iron84,85 and four primary
studies that used intravenous iron86,87,88,89. The use of iron
led to a reduction of 3.8 points in RLS Severity Scale, and
dopaminergic agonists reduce an average of 5.7 points.
The effect appears to be discreet, but the studies presented
other problems such as sample size, dose, and length of fol-
low-up. A recommendation for all studies is to avoid the
intravenous formulations of high molecular weight, such
as iron dextran. The formulations of iron sucrose, and
iron-saccharate carboxymaltose have low molecular weight.
The iron-saccharate (hidroxisaccharate iron III) is available
in Brazil.
The oral iron used in the two studies was ferrous sulfate
at a dose of 325 mg two times a day.The intravenous iron
was used in different ways. One study employed 30 mg IV
iron to test and after 1 hour if no adverse reaction occurred,
plus 970 mg was infused over 3 hours. Another study used
two doses of 500 mg of iron ( ferric carboxymaltose) diluted
in 100 ml saline, both applications being spaced 5 days.
Another way to use the intravenous iron was 200 mg iron
sucrose repeated five times over 3 weeks.
The conclusion of this consensus on the use of iron in
the treatment of RLS is that there is no robust evidence
to indicate or contraindication of their use. Thus, the
use of iron in the treatment of RLS should be decided
by the physician involved in patient care, considering
the studies currently available. The patient should be
informed about the side effects and possible benefit
unrepresentative.
Table 7. Alpha delta ligants drugs and level of evidence.
Treatment Selected articles Number of patients/controls Doses (mg) Recomendations
Gabapentin 2 30/22 300-2,400 I B
Garcia-Borreguero D et al., 2002 22/22 600-2,400
Svenja H, et al., 2003 8/0 300
Gabapentin (IRC) 2 31/16 125-300 I B
Thorp ML et al., 2001 16/16 200-300
Micozkadioglu H et al., 2004 15/0 125-200
Pregabalin 3 144/51 50-450 I B
Allen R et al., 2010 114/23 50-450
Garcia-Borreguero D et al., 2010 30/28 150-450
Pregabalin (neuropathy) 1 16/0 150-600 I B
Sommer M et al., 2007 16/0 150-600
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OTHER TREATMENTS
On the role of other drugs and non-pharmacological treat-
ment of RLS, the information available comes from isolated
studies with short term follow-up and, mostly, with very few
patients. The data indicate that drugs such as carbamazepine,
clonidine and sodium valproate are likely to be effective while
valerian and bupropion are ineffective, but the level of evid-
ence for this evaluation is low. Are evenmore limited and thus
insufficient evidence concerning the use of clonazepam, botu-
linum toxin and non-pharmacological measures. Data on
drugs andmethods evaluated by at least one randomized con-
trolled study are described below (level of evidence 2b).
TREATMENT WITH OTHER DRUGS
Carbamazepine
There is a large randomized, placebo-controlled, double
blind trial that showed significant improvement in the fre-
quency and severity of RLS symptoms after 3 and 5 weeks
of administration of carbamazepine 100 to 300 mg at bed-
time90. About 40% of patients and 23% of controls reported
side effects, but there were no serious reactions. Another
randomized, placebo-controlled study evaluated only 6
patients and demonstrated benefits in the frequency and
intensity of demonstrations at a dose of 600 mg daily91.
The two studies dating from the 80s and used subjective
measures for assessing clinical improvement.
Sodium valproate
A randomized, placebo-controlled, double-blind and
cross-over trial compared 600 mg sodium valproate (VPA)
to 200 mg levodopa, both in slow release formulations, in
the treatment of 20 patients with idiopathic RLS, symptoms
daily for the past six months and PLM index greater than
10/h92. After three weeks of treatment with VPA it was
observed decrease in the intensity and duration of symp-
toms and reduction of sleep latency, but no change in
PLM índex or other PSG parameters. Adverse events were
reported by 45% of patients when on placebo, 45% of
patients when using VPA and 65% when levodopa, but not
severe reactions were observed and no patient had to dis-
continue the use of medication. At the end of the study, 13
patients remained using VPA and, after 18 months, effective-
ness remained in 75% of patients92.
Clonazepam
Two small randomized, double-blind controlled, cross-
over studies evaluated the effect of clonazepam in RLS
symptoms: in 6 patients 0.5 mg at bedtime for 4 weeks
showed no significant improvement in Clinical Global
Impression scales of improvement93; while in another study,
also with 6 patients, 1mg at bedtime for 3 weeks promoted
Table 9. Opioids: recomended doses and side effects.
Opioids
Total dose (mg)
1-4 x day
Adverse effects
Codeine 30-1204
constipation, sedation, possible risk for development or worsening of sleep respiratory disturbances,
risk of abuse in predisposed patients4 (lower risk of augmentation than dopaminergic agents6,7).
Di-hidrocodeine 60-2404
Metadone 5-405,6
Oxicodone 5-203,4
Propoxifen 65-2604
Tilidine 25-1004
Tramadol 50-1501
100-4002
Table 8. Original individual studies and level of evidence for opioids.
Treatment Original articles n pat/control Total dose (mg) Recomendation
Lauerma H & Markkula J., 1999 12 Tramadol (50-150) III C
Walters A et al., 1993 11 (x-over) Oxycodone (5-20) II B
Walters A et al., 2001* 36/0
Codeíne (30-120) Di-hidrocodeíne (60-240)
Methadone (10-40) Oxycodone (5-20)
Tilidine (25-100) Propoxyphene (65-260)
IV C
Ondo WO, 2005 27/0 Methadone (5-40) IV C
Silver et al., 2011* 76/0 Methadone (5-40) IV C
x-over; *Outcomes of tolerability and not efficacy.
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subjective improvement in sleep94. A placebo-controlled, sin-
gle-blind study evaluated the effect of only 1mg dose of clo-
nazepam in polysomnographic parameters of 10 patients
with RLS and it was observed an increase in total sleep time
and sleep efficiency, reduction in the number of arousals and
time awake after sleep onset, with no change in the rates of
periodic movements of members (PLM)95.
Clonidine
In a randomized, placebo-controlled, double-blind, cross-
over trial, 0.5 mg of clonidine at bedtime for three weeks
caused a reduction of sleep latency and improved symptoms
of unpleasant sensations, motor restlessness and daytime
fatigue . The side effects were frequent, but mild96.
Valerian
The effect of valerian was tested in a small randomized , pla-
cebo-controlled, double-blind study in which the intake of
800 mg (1.16 mg of valerenic acids) 1 hour before bedtime for
8 weeks caused no significant improvement in sleep latency,
in the excessive daytime sleepiness or in the severity scale of
RLS97.
Bupropion
Bupropion dose of 150 mg administered two hours before
sleep was evaluated in a randomized, placebo-controlled,
double-blind study. The statistical significance of the
improvement of RLS severity score observed in the first 3
weeks of use not remained after 6 weeks, and there were
no differences when compared to placebo98.
Botulinum Toxin
Intramuscular injection of botulinum toxin in 3 patients
caused no significant improvement in RLS severity score
after 4 weeks, compared to saline injection in a rando-
mized, placebo-controlled, double blind study99. In an
open study with 8 patients, the intramuscular injection of
botulinum toxin also showed no improvement in severity
score after 12 weeks, but has shown improvement in
4 weeks100.
NON-PHARMACOLOGICAL TREATMENTS
Physical exercise
A randomized controlled study evaluated the effect of an
aerobic a low-resistance exercise program 3 times a week.
Significant reduction of RLS severity score was observed
after 6 weeks and was maintained after 12 weeks101.
Intermittent pneumatic compression
A randomized, placebo-controlled, double-blind study of
intermittent pneumatic compression 1 hour daily for 4
weeks showed a significant improvement in RLS severity
score, excessive daytime sleepiness, fatigue and quality of
life102.
Infrared light
In a randomized, placebo-controlled study sessions of
infrared light held 3 times a week for 4 weeks promoted a
significant reduction in the severity score from the second
week of treatment and was maintained in all evaluations
until a week after the suspension of the sessions103. In open
assessment after four weeks of the closing sessions, 67% of
patients reported worsening of symptoms126 .
Acupuncture
According to a systematic review, there is insufficient
evidence to determine whether acupuncture is effective
and safe for treatment of RLS104. Among fourteen potentially
relevant studies, only two met the inclusion criteria but still
had methodological limitations. One showed slight but sig-
nificant improvement in the frequency and intensity of
RLS symptoms, while the other study included in the review
showed no difference104.
Other non-pharmacologic treatments
A randomized, placebo-controlled study, involving only 4
patients and 2 controls, using the technique of facilitated
external counterpulsation for treatment of RLS showed no
reduction in the severity score105.
AUGMENTATION
Augmentation was initially described as a serious wor-
sening of RLS symptoms in a long-term treatment with
levodopa106. However, subsequent studies have shown the
occurrence of augmentation with all dopamine agonists107.
Among the risk factors for the occurrence of augmen-
tation are the use of selective serotonin reuptake inhibitors
of serotonin and norepinephrine, antihistamines and chronic
loss of iron, but the data are not definitive108. The state of
clinical severity of RLS pre-treatment (daily or refractory
forms) as well as aging are risk factors for the development
of augmentation. However, gender does not represent addi-
tional risk. Likewise, there are no reports of augmentation
with antiepileptic or opioids (except to tramadol)109.
Five to seven percent was the estimated incidence,
according to 10 years follow-up trial performed with patients
taking dopamine agonists and, in up to 35% of patients, the
augmentation was responsible for the treatment disconti-
nuation106.
Allen and colleagues have recently shown an incidence
of 8% in a poll online study using defined diagnostic
criteria108.
272 Arq Neuropsiquiatr 2015;73(3):260-280
The clinical definition and initial approach of
Augmentation were hampered by the absence of specific
clinical criteria, but the situation began to change after the
meetings of experts and the determination of the criteria
of the National Institutes of Health (NIH) in 2002. These cri-
teria were subject to revaluation in the international sym-
posium held in Munich in 2006 (Max Planck Institute-
MPI), which caught the attention of the clinical significance
and severity of symptoms of augmentation4.
The clinical definition of augmentation follows this order
of symptoms108:
Criterion 1: Sensory-motor symptoms occur at least 2
hours earlier than usual
Criterion 2: Two or more of the following:
N Worsening of symptoms with increasing dose and
improvement with its reduction;
N Lower latency of symptoms onset after entry into resting
state;
N Expansion Space (need to move extends to body regions
previously unaffected). Shorter duration of dose effect in
relation to starting treatment;
N Periodic limb movements arise or worsen during
wakefulness arise.
Attention:
(1) Symptoms of augmentation must be present for at
least 2 weeks, 5 days a week;
(2) Absence of psychiatric, behavioral, medical, phar-
macological disturbances that justify the symptoms.
Rebound, tolerance and progression of RLS are phenom-
ena that must be differentiated clinically from augmentation
because of its consequences for the therapeutic decision.
Rebound (25%) is the reappearance of symptoms and
intensification after the end of dose effect.
Tolerance is the loss of therapeutic effect of a certain
dose of medicament. Some authors have even claimed that
the habitual use of low doses of dopaminergic agents could,
in some cases, result in tolerance with loss of therapeutic
efficacy, need for dose escalation and eventual favoring aug-
mentation106. However, in general, increasing the dose leads
to elimination of symptoms of tolerance, unlike what occurs
in augmentation.
Progression is a slow and gradual increase in the intens-
ity of symptoms without temporal or spatial expansion, in
patients using dopamine agonists, dopamine precursors,
opioids, antiepileptic drugs or other classes of medications
and can represent the characteristic fluctuation that hap-
pens in this syndrome.
Clinical experience suggests approaching augmentation
by defining the severity of the condition as follows109:
(a) Interference with activities of daily living and/or beha-
vior (stop using the car or driving in the afternoon);
(b) Negative impact on quality of life (sleep, mood);
(c) Need to change treatment (increase or split doses or
change the schedule);
(d) Add adjunctive or concomitant medications to SPI
(analgesics, hypnotics);
(e) Other aspects considered by the physician (must be
specified).
In these cases a change in the treatment regimen may be
necessary. Roughly speaking, if the augmentation symptoms
occur with use of dopamine agonists, the first step should be
chosen initially for an advance schedule of dose and, if
necessary, their reduction and division in multiple schedules.
Alternatively, we can opt for the non-dopaminergic treat-
ment with GABAergic antiepileptic drugs (gabapentin, preg-
abalin) or opioids. However, further studies are needed to
definitively say that this change in regimen is really effective
in improving augmentation symptoms or in its prevention132.
Recent studies have demonstrated the efficacy of new
RLS treatments, with whom would be the lowest rate of
onset or prone to the phenomenon of augmentation (rotigo-
tine patches, gabapentin enacarbil XR)110,111.
Finally, it must be emphasized the efficacy of opioids,
particularly methadone, not only treating the symptoms of
RLS as well as reducing the symptoms of augmentation
and restoring sleep86,109.
SPECIAL SITUATION: RESTLESS LEGS SYNDROME
IN CHILDREN
General Aspects
Ekbom (1945) was the first to describe the symptoms and
use the term Restless Legs Syndrome112. In this series of
cases, Ekbom already cites the presence of the syndrome
since childhood, and in 12 patients there was a report of
symptoms that begun between 10 and 19 years old. After
this initial description of RLS in children by Ekbom, only
in the mid-90s were the first case reports and case series
on pediatric RLS. In 1994, Walters et al.2 reported the cases
of four children with RLS, three of the same family113.
The diagnosis of RLS remains largely clinical with the dia-
gnostic criteria for RLS in children in uniform in 2003 by the
International Study Group on Restless Legs Syndrome
(IRLSSG)9.
Diagnosis and epidemiology
Diagnosis
The International Study Group on Restless Legs
Syndrome (IRLSSG) proposed criteria for diagnosis in 1995,
which were recently reviewed9,114. Diagnostic criteria for chil-
dren were also defined for ages 2 to 12 years and above 12
years of age, as proposed by IRLSSG in three levels of
demand, namely, defined RLS, probable and possible RLS,
as shown below.
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A. Diagnostic criteria for defined RLS in children: (*)
The child must meet all four criteria used for RLS in
adults:
(i) A desire to move the legs associated with discomfort;
(ii) Relief from this feeling with the movement;
(iii) The occurrence or worsening of symptoms in the rest
position;
(iv) The occurrence or worsening of symptoms in the
evening;
Associated to:
The child does describe the symptoms in their own
words, which must be consistent with the complaint of dis-
comfort in the lower limbs.
Or:
I. The child meets all the criteria for RLS for adults.
Associated to:
II. Two of the three criteria for support:
(i) Sleep disturbance for age;
(ii) Biological parents or siblings show RLS;
(iii) The child has periodic leg movement índex on PSG
(PLM) . 5 / hour of sleep .
B. Diagnostic Criteria for probable RLS diagnosis in chil-
dren
(i) The child meets all four RLS criteria for adults,
except for item # 4, i.e the occurrence or worsening of
symptoms in the evening;
(ii) The child has a biological parent or sibling with
definite RLS.
Or:
(i) The child is seen presenting manifestations of lower
extremity discomfort when sitting or lying down,
accompanied by movements of the affected limb and
discomfort has characteristics worsen with rest and
inactivity, being relieved by movement and worse at
night;
(ii) The child has a biological parent or sibling with
definite RLS.
C. Diagnostic Criteria for possible RLS in children
(i) The child has a disorder of periodic limb movements;
(ii) The child has a biological parent or sibling with RLS, but
does not meet the criteria for definite or probable RLS.
Legend: (*) The criteria used for children older than 13
years are the same as those used for adults.
The great difficulty in making the diagnosis of RLS in
children is due to their lower ability in verbal language, mak-
ing dificult the subjective description of symptoms, espe-
cially when children belong to younger age groups115.
Under the ICSD, the differential diagnosis should be done
with positional discomfort, hípnicas myoclonus, akathisia,
cramps and other sleep-related conditions that produce
chronic pain, such as arthritis, peripheral vascular diseases,
sports injuries secondary to trauma and sensory neuropa-
thies. Some of these diseases can present nocturnal pains
that worsen with immobility and can also be relieved with
movement, but the movement of light intensity rarely eases
it112. In children, it is worth mentioning the importance of
differential diagnosis with growing pains (GP).
Comorbidities
Among the major comorbidities of Pediatric RLS we have:
GP, psychiatric disorders, often associated with attention-
deficit/hyperactivity disorder (ADHD).
Growing Pains (GP)
This entity is defined as a discomfort in the legs that
occurs in school-age children, with diagnostic criteria sug-
gested by Peterson in the decade of 1980116. From the 70’s
there were the first epidemiological studies on growing
pains.
Rajaram et al.28 observed that ten children of a group of
eleven, followed up with neurologist specializing in ADHD,
and who had previously received a diagnosis of GP, had
RLS according to the definied criteria of IRLSSG9. Thus, they
reported that there may be diagnostic confusion between GP
and RLS, when the adequate diagnostic criteria for both dis-
eases are not well applied.
Walters found no consistent pattern in the descriptions
of RLS and GP in childhood, even when it was not joint
pain117. He described as unlikely the possibility that all RLS
patients had GP and vice versa.
Psychiatric disorders
The presence of insomnia and detection of PLM disorder
in children with ADHD have led to the evaluation of the pos-
sible relationship between these entities. Studies in children
with ADHD have shown RLS incidence from 11.5 to 44%118.
The presence of cognitive impairment and ADHD has been
associated with RLS and PLMs in adults and children. The
relationship between RLS and ADHD could occur in several
ways: 1) the sleep disorder with poor quality and multiple
arousals associated with PLM and RLS could lead to inatten-
tion and hyperactivity; 2) RLS and PLM could be co-morbid
with ADHD; 3) RLS and PLM, and a subgroup of ADHD
could share the same pathophysiological mechanisms of
dopaminergic dysfunctioning or changes on iron
metabolism; 4) diurnal manifestations of RLS could mimic
ADHD symptoms118,119.
In a study of Walters and colleagues some children with
ADHD and PLM and RLS symptoms after specific treatment
for RLS and PLM, when there was an improvement of RLS
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symptoms was also observed improvement on behavior120.
Genetic study suggested the possibility of linking the gene
BTBD9, related to iron storage and SPI, and some subgroups
of patients with ADHD121. Another study, evaluating the
medical records of 374 children and adolescents with RLS
showed that 64% of them had some psychiatric comorbidity:
mood disorder in 29.1% of cases, ADHD in 25%, anxiety in
11.5% and severe behavior in 10.9%122.
Epidemiology
The prevalence of RLS in children was not established
until recently. However, in the series of Walters and collea-
gues123, in 1996, a third of adults with RLS reported that their
symptoms began before the age of 10, and up to 40% of
adults before the age of 20.
Two studies on the prevalence of RLS performed in chil-
dren found rates of 31.7% and 5.9% respectively124,125. The
study by Laberge and colleagues125 in Canada, assessed the
prevalence and interactions between certain sleep disorders.
In total, 1,353 children aged between 6 and 16 years old, based
on diagnostic criteria for RLS in adults and followed by three
consecutive years, 6.1% of the sample kept the RLS symptoms
uninterruptedly. There was a significant predominance of girls
(56.8%) than boys (43.2%) and no association was found
between RLS and any other type of assessed sleep disorder.
Kinkelbur, Hellwig and Hellwig evaluated, in 2003 in
Germany, the frequency of RLS in patients from pediatric
practices, aged between 6 and 17 years old. They used a
questionnaire to evaluate the association between dysesthe-
sia relieved by movement and worsening at night. In a group
of 1,084 children and adolescents, the frequency of involve-
ment was 1.3% and there was no gender predominance126.
Kotagal and Silber127, in 2004, reviewed the medical
records of 538 children followed for four years in a pediatric
sleep service and applied diagnostic IRLSSG criteria. The
diagnosis of RLS was performed in 11.5% of children under
18 y.o. However, when applied to the most recent RLS cri-
teria, only 5.9% were diagnosed as suffering from RLS. The
age of onset for cases with definite RLS was 9.7 years old and
probable RLS was 7.4 years. The most common complaints
among children were: insomnia in 87.5%; involuntary move-
ments of the limbs in 31%, chronic fatigue in 28%, and inatten-
tion in 25% and sleepwalking in 9.3%. A family history of RLS
was present in 71% of cases and ferritin was below 50 ng/dl
in 83% of cases in which it was measured (75% of children).
In 2007, Picchietti and colleagues124 conducted a study to
assess the prevalence of RLS in children, using the criteria of
IRLSSG. A prevalence of 1.9% of children between 8 and 11
years old, and 2.0% of children between 12 and 17 years old.
It was also observed that children and adolescents with RLS
presented insomnia in 69.4%, 47%-53% reported negative
influence on mood, 46%-60% complained of inability to remain
seated in the afternoon or evening, 29%-40% complained of T
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lack of energy and, among adolescents, 40% reported difficulty
concentrating in school or work tasks.
In 2009, Sander et al . studied the population of school-age
children in the city of the Coconut Cassia, SP, and found a pre-
valence of 6.3% of defined RLS128. In a epidemiological study con-
ducted in Turkey in 2011, with children and adolescents of
school age, the prevalence of defined RLSwas 2.74%129. Themain
epidemiological studies in children are compiled in Table 10.
Treatment
Treatment for Pediatric RLS is also divided into non-
pharmacological and pharmacological. However, it is note-
worthy that there are no studies with level I evidence to
guide therapeutic choices of RLS in children. The non-phar-
macological treatment consists in improve sleep hygiene:
encourage regular physical activity and improve sleep rou-
tines in order to avoid sleep deprivation and exacerbating
factors such as caffeinated substances130,131.
Pharmacological treatment is mainly based on the orally
replacement of iron. Similar to the treatment in adults, dopa-
mine agonists, anticonvulsants, benzodiazepines are referred
to series of cases in the literature (level II evidence).
Oral iron is given for children and adolescents with
serum ferritin less than 50 ng/dl. In children above 6 years
of age is recommended the use of 50-60 mg of elemental iron
1-2x/day, controlling with exams every 2-3 months1. Among
the anticonvulsants, there are case reports of the use of
valproate, carbamazepine and gabapentin. Clonazepam is
an option in cases where there are other sleep disorders
(eg parasomnias) or epilepsy associated with RLS. The use
of clonidine is cited in cases with comorbid RLS and
ADHD. As for dopaminergic agents, studies with levodopa
in children showed no safety and efficacy. There are few
reports with the use of pramipexole. Regarding the opioids,
which are often used in adults, they should be AVOIDED
in childhood (Table 11).
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